Stimulation of S91 melanoma tyrosinase activity by superpotent alpha-melanotropins. 1985

M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci

alpha-Melanocyte-stimulating hormone (alpha-MSH, alpha-melanotropin), [Nle4,D-Phe7]-alpha-MSH and related fragment analogues, Ac-[Nle4,D-Phe7]-alpha-MSH4-11-NH2 and Ac-[Nle4,D-Phe7]-alpha-MSH4-10-NH2, were studied for their ability to stimulate tyrosinase activity in Cloudman S91 mouse melanoma cells in tissue culture. All of the melanotropins stimulated tyrosinase activity in a dose-dependent manner. [Nle4,D-Phe7]-alpha-MSH was about 100 times more active than alpha-MSH as determined from the minimal effective dose (MED) required to activate the enzyme above control (basal) levels. The MED of this analogue to significantly stimulate tyrosinase activity at 24, 48 and 72 h of incubation was 10(-11) M whereas the MED of alpha-MSH was 10(-9) M at each of these times. The maximum tyrosinase activity achieved from the time of initial incubation in the presence of [Nle4,D-Phe7]-alpha-MSH was approximately 3-, 5- and 6-fold greater than control levels at 24, 48 and 72 h, respectively. The 2 [Nle4,D-Phe7]-substituted fragment analogues were at least as active as the tridecapeptide analogue and therefore at least 100-fold more active than alpha-MSH in stimulating enzyme activity. These [Nle4,D-Phe7]-substituted analogues were more active in the melanoma tyrosinase assay than in the melanoma adenylate cyclase assay or other normal melanocyte (frog and lizard skin) bioassays.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009074 Melanocyte-Stimulating Hormones Peptides with the ability to stimulate pigmented cells MELANOCYTES in mammals and MELANOPHORES in lower vertebrates. By stimulating the synthesis and distribution of MELANIN in these pigmented cells, they increase coloration of skin and other tissue. MSHs, derived from pro-opiomelanocortin (POMC), are produced by MELANOTROPHS in the INTERMEDIATE LOBE OF PITUITARY; CORTICOTROPHS in the ANTERIOR LOBE OF PITUITARY, and the hypothalamic neurons in the ARCUATE NUCLEUS OF HYPOTHALAMUS. MSH,Melanocyte Stimulating Hormone,Melanocyte-Stimulating Hormone,Melanophore Stimulating Hormone,Melanotropin,MSH (Melanocyte-Stimulating Hormones),Melanophore-Stimulating Hormone,Hormone, Melanocyte Stimulating,Hormone, Melanocyte-Stimulating,Hormone, Melanophore Stimulating,Melanocyte Stimulating Hormones,Stimulating Hormone, Melanocyte,Stimulating Hormone, Melanophore
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004156 Catechol Oxidase An enzyme of the oxidoreductase class that catalyzes the reaction between catechol and oxygen to yield benzoquinone and water. It is a complex of copper-containing proteins that acts also on a variety of substituted catechols. EC 1.10.3.1. Diphenol Oxidases,Diphenol Oxidase,Polyphenol Oxidase,Polyphenoloxidase,Oxidase, Catechol,Oxidase, Diphenol,Oxidase, Polyphenol,Oxidases, Diphenol
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
June 1998, The journal of peptide research : official journal of the American Peptide Society,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
May 1993, Annals of the New York Academy of Sciences,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
February 1986, In vitro cellular & developmental biology : journal of the Tissue Culture Association,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
July 1983, Journal of cellular physiology,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
November 1985, The Journal of investigative dermatology,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
June 1975, Nature,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
September 1990, Photochemistry and photobiology,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
January 1961, Biologica Latina,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
May 1987, Molecular and cellular endocrinology,
M M Marwan, and Z A Abdel Malek, and K L Kreutzfeld, and M E Hadley, and B C Wilkes, and V J Hruby, and A M Castrucci
June 1970, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!